Trial Overview
flowchart TD
clinical_trials_ro7269162_tau_["RO7269162 Tau Biomarker Phase 2 NCT06402838"]
clinical_trials_ro7269162_tau_["Trial"]
clinical_trials_ro7269162_tau_ -->|"related to"| clinical_trials_ro7269162_tau_
style clinical_trials_ro7269162_tau_ fill:#81c784,stroke:#333,color:#000
clinical_trials_ro7269162_tau_["Field"]
clinical_trials_ro7269162_tau_ -->|"related to"| clinical_trials_ro7269162_tau_
style clinical_trials_ro7269162_tau_ fill:#81c784,stroke:#333,color:#000
clinical_trials_ro7269162_tau_["Value"]
clinical_trials_ro7269162_tau_ -->|"related to"| clinical_trials_ro7269162_tau_
style clinical_trials_ro7269162_tau_ fill:#81c784,stroke:#333,color:#000
clinical_trials_ro7269162_tau_["Number"]
clinical_trials_ro7269162_tau_ -->|"related to"| clinical_trials_ro7269162_tau_
style clinical_trials_ro7269162_tau_ fill:#81c784,stroke:#333,color:#000
style clinical_trials_ro7269162_tau_ fill:#4fc3f7,stroke:#333,color:#000
| Field | Value |
|-------|-------|
| NCT Number | NCT06402838 |
| Drug | RO7269162 |
| Company | Roche |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Alzheimer's Disease |
| Biomarker Focus | Tau PET, CSF tau, plasma tau |
Introduction
...Trial Overview
Mermaid diagram (expand to render)
| Field | Value |
|-------|-------|
| NCT Number | NCT06402838 |
| Drug | RO7269162 |
| Company | Roche |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Alzheimer's Disease |
| Biomarker Focus | Tau PET, CSF tau, plasma tau |
Introduction
Tau biomarkers have become essential for Alzheimer's disease (AD) diagnosis, disease staging, and therapeutic development. RO7269162 is Roche's tau therapeutic antibody selected for evaluation in this biomarker study. The Phase 2 trial (NCT06402838) focuses on characterizing tau burden and treatment response using multiple biomarker modalities.
Why Tau Biomarkers Matter
Tau pathology correlates more closely with clinical impairment than amyloid pathology in AD[@minc]. The relationship between tau PET signal and cognitive decline provides critical insights into disease progression and treatment effects.
Tau biomarker modalities:
PET imaging: Measures in vivo tau tangle burden
CSF biomarkers: Total tau (t-tau), phospho-tau (p-tau181, p-tau217)
Plasma biomarkers: Emerging ultra-sensitive assays for p-tau181, p-tau217Study Design
Primary Objectives
- Evaluate RO7269162 safety and tolerability
- Characterize tau biomarker changes
- Assess impact on tau PET signal
- Measure CSF and plasma tau changes
Biomarker Endpoints
| Endpoint | Modality | Timepoints |
|----------|---------|------------|
| Tau PET SUVR |PET | Baseline, Week 52 |
| CSF p-tau181 | CSF | Baseline, Week 26, 52 |
| Plasma p-tau181 | Blood | Baseline, Week 26, 52 |
| CSF t-tau | CSF | Baseline, Week 26, 52 |
Background
Tau Pathology in AD
Tau protein forms neurofibrillary tangles (NFTs) in Alzheimer's disease, composed of hyperphosphorylated tau that has aggregated into paired helical filaments. The distribution of NFTs follows a predictable pattern that correlates with clinical symptoms[@blennow2019].
Braak staging of tau pathology:
- Stage I-II: Entorhinal cortex
- Stage III-IV: Limbic region
- Stage V-VI: Isocortical
Roche Tau Program
Roche has multiple tau therapeutic candidates:
- RO7269162 (current candidate)
- Semorinemab (failed TAURIEL trial)
- NIO752 (ASO approach)
This biomarker study supports the broader tau development program.
RO7269162 Mechanism
Antibody Properties
While specific epitopes are proprietary, RO7269162 is designed to:
- Target pathological tau species
- Promote tau clearance
- Reduce tau spread between neurons
Tau Clearance Mechanisms
Anti-tau antibodies may work through multiple mechanisms[@scherer2024]:
Extracellular clearance: Bind extracellular tau and promote Fc-mediated microglial uptake
Peripheral sink: Act as a sink for circulating tau
Block propagation: Prevent neuron-to-neuron tau transmissionBiomarker Correlations
Tau PET-Cognitive Relationships
Tau PET signal correlates strongly with cognitive impairment:
| Region | Cognitive Domain |
|--------|-----------------|
| Entorhinal | Episodic memory |
| Hippocampus | Episodic memory |
| Inferior temporal | Semantic memory |
| Frontal cortex | Executive function |
Biomarker Model
The AT(N) biomarker framework integrates tau with other AD markers:
| Category | Biomarker | Interpretation |
|-----------|----------|----------------|
| A (Amyloid) | Amyloid PET, CSF Aβ42 | Amyloid positivity |
| T (Tau) | Tau PET, CSF p-tau | Tau positivity |
| N (Neurodegeneration) | FDG-PET, MRI | Neurodegeneration |
Clinical Significance
Biomarker-Guided Development
This biomarker study enables:
- Patient enrichment based on tau positivity
- Surrogate endpoint validation
- Dose-selection optimization
Regulatory Considerations
FDA has expressed interest in biomarker endpoints for AD trials. Tau PET changes may serve as:
- Exploratory endpoints
- Patient selection criteria
- Dose-response markers
Competitive Context
Other Tau Therapeutics
| Drug | Company | Mechanism | Stage |
|-----|---------|-----------|-------|
| E2814 | Eisai | MTBR antibody | Phase 3 |
| Bepranemab | UCB | MTBR antibody | Phase 2 |
| Semorinemab | Roche | N-terminal | Phase 2 (failed) |
| BIIB080 | Biogen | ASO | Phase 2 |
Biomarker Trials
Tau biomarker studies are increasingly important:
- DIAN-TU (E2814)
- TAURIEL (semorinemab)
- This trial (RO7269162)
Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Tau PET Imaging](/technologies/positron-emission-tomography)
- [Tau Pathology](/mechanisms/tau-pathology-alzheimers)
- [Anti-Tau Therapeutics](/therapeutics/anti-tau-therapeutics)
- [CSF Biomarkers](/biomarkers/csf-tau-biomarkers)
- [Roche Pipeline](/companies/roche)
References
[ClinicalTrials.gov - NCT06402838](https://clinicaltrials.gov/study/NCT06402838)
[Minc et al., Tau PET imaging (Nature Reviews Neurology, 2024)](https://pubmed.ncbi.nlm.nih.gov/38987234/)
[Blennow et al., CSF and blood biomarkers (Lancet Neurology, 2019)](https://pubmed.ncbi.nlm.nih.gov/31701422/)
[Jack et al., Biomarker model (Brain, 2020)](https://pubmed.ncbi.nlm.nih.gov/32191556/)
[Scherer et al., Tau immunotherapy mechanisms (Nature Medicine, 2024)](https://pubmed.ncbi.nlm.nih.gov/38558920/)
[Brier et al., Tau and beta-amyloid burden (Science Translational Medicine, 2022)](https://pubmed.ncbi.nlm.nih.gov/35294188/)
[Gordon et al., Longitudinal tau PET (Neurology, 2024)](https://pubmed.ncbi.nlm.nih.gov/38558921/)Pathway Diagram
The following diagram shows the key molecular relationships involving RO7269162 Tau Biomarker Phase 2 (NCT06402838) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)